A322970 Stock Overview
Develops gene therapies based on its proprietary gene-editing platform technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Moogene Medi Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,490.00 |
| 52 Week High | ₩3,505.00 |
| 52 Week Low | ₩1,350.00 |
| Beta | 0 |
| 11 Month Change | -11.23% |
| 3 Month Change | 39.57% |
| 1 Year Change | -4.23% |
| 33 Year Change | -41.89% |
| 5 Year Change | n/a |
| Change since IPO | -58.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| A322970 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -12.9% | -5.8% | -2.8% |
| 1Y | -4.2% | 28.2% | -3.4% |
Return vs Industry: A322970 underperformed the KR Biotechs industry which returned 28.2% over the past year.
Return vs Market: A322970 matched the KR Market which returned -3.4% over the past year.
Price Volatility
| A322970 volatility | |
|---|---|
| A322970 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A322970's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A322970's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.moogene.com |
Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease.
Moogene Medi Co., Ltd. Fundamentals Summary
| A322970 fundamental statistics | |
|---|---|
| Market cap | ₩24.94b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A322970 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A322970 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A322970 perform over the long term?
See historical performance and comparison